Category: CovidienSyndicate content

Covidien hunts for new CFO | Personnel Moves

January 29, 2014 by Chris Walker

Covidien CFO Charles Dockendorff plans to retire at the end of 2014, leaving a vacancy in a role he's filled for 25 years.

fired/hired

Covidien (NYSE:COV) said it's searching for a new CFO after Charles Dockendorff announced his plans to retire from the company at the end of 2014.

Dockendorff has been with the company since 1989, serving in a variety of finance-related roles. He was named CFO of Covidien predecessor Tyco Healthcare in 1995, helping lead the company to $10 billion in sales in 2007.

Covidien reports 19% profit dip and notches a win in J&J patent battle

January 24, 2014 by Arezu Sarvestani

Covidien beats Wall Street's Q1 expectations despite a 19% profit dip, and the company touts a patent infringement win against Johnson & Johnson subsidiary Ethicon Endo-Surgery.

Covidien hits Q1 target and notches a win in J&J patent battle

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien opens 1st India Center of Innovation

January 23, 2014 by Arezu Sarvestani

Massachusetts medical device maker Covidien opens a Center of Innovation in China, planning 3 more centers this year in emerging markets.

Covidien opens 1st India innovation center

True to its promises, Covidien (NYSE:COV) is making big strides in emerging markets, today announcing the opening of its 1st Center of Innovation in India.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien lands FDA 510(k) for 3-in-1 laparoscopic surgical device

January 23, 2014 by Chris Walker

Covidien touts 510(k) clearance for its LigaSure Maryland jaw open/laparoscopic sealer/divider.

Covidien lands FDA 510(k) for laparoscopic surgical device

Covidien (NYSE:COV) won 510(k) clearance from the FDA for its LigaSure Maryland jaw open/laparoscopic sealer/divider, the company announced this week.

Covidien bails on renal denervation

January 21, 2014 by Brad Perriello

Covidien said it's pulling the plug on its OneShot renal denervation device, citing the slow development of the hypertension market.

Covidien bails on renal denervation

Covidien (NYSE:COV) said it plans to wind down its OneShot renal denervation program, largely due to "slower than expected development of the renal denervation market," meaning the end for a U.S. clinical trial of the high blood pressure device.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

J.P. Morgan medtech wrap-up: Ups and downs from San Francisco

January 16, 2014 by MassDevice staff

In case you couldn't make it to sunny San Francisco, here are some of the best medical device stories that came out of the J.P. Morgan Healthcare conference this week.

J.P. Morgan medtech wrap-up: Ups and downs from San Francisco

Medtronic CEO: Value-based healthcare is the only way to save medtech

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien closes $235M divestiture of Confluent to Integra LifeSciences

January 16, 2014 by Arezu Sarvestani

Covidien hands its Confluent Surgical product line over to Integra LifeSciences in a deal worth up to $260 million.

Covidien closes $235M divestiture of Confluent to Integra LifeSciences
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp